Russell Investments Group Ltd. Increases Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Russell Investments Group Ltd. lifted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 39.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 70,314 shares of the company's stock after buying an additional 19,917 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.09% of IDEXX Laboratories worth $29,066,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Centiva Capital LP bought a new stake in IDEXX Laboratories in the 3rd quarter worth approximately $211,000. Janus Henderson Group PLC raised its stake in IDEXX Laboratories by 0.4% during the third quarter. Janus Henderson Group PLC now owns 11,834 shares of the company's stock valued at $5,978,000 after purchasing an additional 53 shares in the last quarter. IHT Wealth Management LLC raised its stake in IDEXX Laboratories by 32.9% during the third quarter. IHT Wealth Management LLC now owns 666 shares of the company's stock valued at $335,000 after purchasing an additional 165 shares in the last quarter. Wellington Management Group LLP lifted its position in IDEXX Laboratories by 35.7% during the third quarter. Wellington Management Group LLP now owns 74,811 shares of the company's stock valued at $37,796,000 after purchasing an additional 19,663 shares during the last quarter. Finally, Orion Portfolio Solutions LLC grew its stake in shares of IDEXX Laboratories by 16.4% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 4,152 shares of the company's stock worth $2,098,000 after buying an additional 584 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

Remove Ads

IDEXX Laboratories Trading Up 2.0 %

IDXX stock traded up $7.63 during trading on Monday, hitting $398.57. The company had a trading volume of 152,944 shares, compared to its average volume of 615,018. The firm has a market capitalization of $32.30 billion, a P/E ratio of 37.35, a PEG ratio of 3.41 and a beta of 1.50. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $548.88. The company has a 50 day simple moving average of $428.03 and a 200-day simple moving average of $433.60.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP George Fennell sold 9,986 shares of the company's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company's stock.

Analyst Ratings Changes

IDXX has been the topic of several recent research reports. StockNews.com cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday. Bank of America upped their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Barclays boosted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Piper Sandler increased their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Finally, Morgan Stanley cut their price objective on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, IDEXX Laboratories presently has an average rating of "Moderate Buy" and an average target price of $523.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.